48 results on '"Paul Carle"'
Search Results
2. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
3. A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing
4. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
5. Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells
6. Lupus band test can be used in combination with anti-chromatin antibodies and complement analysis to predict transition from cutaneous to systemic lupus
7. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
8. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
9. Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice
10. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
11. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores
12. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
13. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
14. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
15. Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review
16. Clinical meaningfulness of complete skin clearance in psoriasis
17. Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement
18. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis
19. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis
20. JAK inhibition for CD3− CD4+ lymphocytic-variant hypereosinophilic syndrome
21. Knockdown of Filaggrin in a Three-Dimensional Reconstructed Human Epidermis Impairs Keratinocyte Differentiation
22. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
23. 50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms
24. 49730 GUIDE trial (part 3): Following guselkumab withdrawal and a long treatment-free period, disease control is rapidly regained upon re-treatment in psoriasis super-responders
25. 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
26. Why Statistics Matter: Limited Inter-Rater Agreement Prevents Using the Psoriasis Area and Severity Index as a Unique Determinant of Therapeutic Decision in Psoriasis
27. Deimination of Human Filaggrin-2 Promotes Its Proteolysis by Calpain 1
28. In atopic dermatitis patients and in absence of allergen immunotherapy, dupilumab induces a decrease of specific IgE and an increase of specific IgG4
29. 43879 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
30. Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis
31. 33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study
32. 33307 Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis
33. 34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
34. 33566 Early response with ixekizumab predicts long-term outcomes up to 5 years in psoriasis by unsupervised and supervised machine learning analyses
35. Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases
36. Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study
37. 27237 Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE
38. 26573 Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
39. Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway
40. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis
41. 15431 Indirect comparisons in psoriasis: Implications for clinical practice
42. 15059 Baricitinib, an oral reversible Janus kinase 1 and 2 inhibitor, for atopic dermatitis: Head and neck response across two phase 3 studies
43. Bleomycin hydrolase downregulation in lesional skin of adult atopic dermatitis patients is independent of FLG gene mutations
44. Late-Onset X-Linked Dominant Protoporphyria: An Etiology of Photosensitivity in the Elderly
45. Interferon Alpha and Pamidronate in Osteoporosis with Fracture Secondary to Mastocytosis
46. Cancer Risk Evaluation in Psoriasis: In Search of the Holy Grail?
47. Angiolymphoid hyperplasia with eosinophilia treated with low-dose methotrexate
48. Treating Severe Psoriasis: How to Navigate Safely Between Scylla and Charybdis?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.